Phase II clinical trial of didemnin B in previously treated small cell lung cancer

Dong M. Shin, Paul Y. Holoye, Arthur Forman, Rodger Winn, Roman Perez-Soler, Shaker Dakhil, Julian Rosenthal, Martin N. Raber, Waun Ki Hong

Research output: Contribution to journalArticle

31 Scopus citations

Abstract

Didemnin B (NSC 325319), a cyclic depsipeptide isolated from a Carribean sea tunicate, exhibited potent antitumor activity in preclinical studies. After determining the maximum tolerated dose in our previous phase I/II trial, we conducted a phase II study of this drug in patients with previously treated small cell lung cancer; the starting dose was 6.3 mg/m2 intravenously over 30 min every 28 days. The major side effects were in the neuromuscular system and included severe muscle weakness, myopathy and/or myotonia by electromyography, and elevation of creatine phosphokinase and aldolase levels. We also observed modest increases in bilirubin and alkaline phosphatase levels. There were minimal hematologic toxic effects. No response was observed among 15 evaluable patients, leading us to conclude that didemnin B was toxic but inactive in patients with previously treated small cell lung cancer at the stated dose and schedule. A review of the literature revealed no significant antitumor activity in cancers of the colon, breast, ovaries, cervix, or lung (non-small cell) or in renal cell carcinoma. Further clinical trials for didemnin B may not be warranted at the stated dose and schedule.

Original languageEnglish (US)
Pages (from-to)243-249
Number of pages7
JournalInvestigational New Drugs
Volume12
Issue number3
DOIs
StatePublished - Sep 1 1994
Externally publishedYes

Keywords

  • didemnin B
  • myopathy
  • small cell lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase II clinical trial of didemnin B in previously treated small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Shin, D. M., Holoye, P. Y., Forman, A., Winn, R., Perez-Soler, R., Dakhil, S., Rosenthal, J., Raber, M. N., & Hong, W. K. (1994). Phase II clinical trial of didemnin B in previously treated small cell lung cancer. Investigational New Drugs, 12(3), 243-249. https://doi.org/10.1007/BF00873966